Colon Cancer - Pipeline Review, H2 2013


#172031

347pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Colon Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Colon Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Colon Cancer.
  • A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Colon Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Colon Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10

Introduction 11
Global Markets Direct Report Coverage 11
Colon Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Colon Cancer 13
Colon Cancer Therapeutics under Development by Companies 15
Colon Cancer Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Colon Cancer Therapeutics – Products under Development by Companies 28
Colon Cancer Therapeutics – Products under Investigation by Universities/Institutes 36
Companies Involved in Colon Cancer Therapeutics Development 37
AstraZeneca PLC 37
Eli Lilly and Company 38
Viralytics Ltd. 39
Bioneer Corporation 40
Celltrion, Inc. 41
Bio-Path Holdings, Inc. 42
Geistlich Pharma AG 43
Aphios Corporation 44
Cell Therapeutics, Inc. 45
Enzo Biochem, Inc. 46
AEterna Zentaris Inc. 47
ImmunoCellular Therapeutics, Ltd. 48
Idera Pharmaceuticals, Inc. 49
Lorus Therapeutics Inc 50
Bio-Bridge Science, Inc. 51
Bionomics Limited 52
Northwest Biotherapeutics, Inc. 53
Cleveland BioLabs, Inc. 54
OncoVista Innovative Therapies, Inc. 55
Compugen Ltd. 56
Patrys Limited 57
Critical Outcome Technologies Inc. 58
Curis, Inc. 59
Cytokinetics, Inc 60
Telik, Inc. 61
Dendreon Corporation 62
Choongwae Pharma Corp 63
Green Cross Corporation 64
Sareum Holdings plc 65
Transgene Biotek Ltd 66
Rexahn Pharmaceuticals, Inc. 67
MabVax Therapeutics, Inc. 68
Nanobiotix 69
Cancer Research Technology Limited 70
Multimmune GmbH 71
Nerviano Medical Sciences S.r.l. 72
Med Discovery SA 73
Provecs Medical GmbH 74
Alethia Biotherapeutics Inc. 75
NormOxys, Inc. 76
OncoMed Pharmaceuticals, Inc. 77
Five Prime Therapeutics, Inc. 78
Kalos Therapeutics, Inc. 79
AlphaVax, Inc. 80
Azaya Therapeutics, Inc. 81
Deciphera Pharmaceuticals, LLC 82
Mersana Therapeutics, Inc. 83
Affichem 84
Advenchen Laboratories, LLC 85
Pharminox Limited 86
NovaLead Pharma Pvt. Ltd. 87
Vaccinogen, Inc. 88
Etubics Corporation 89
NewLink Genetics Corporation 90
Cellceutix Corporation 91
PharmaMar, S.A. 92
TVAX Biomedical, LLC 93
CG Therapeutics, Inc. 94
Biokine Therapeutics Ltd. 95
Tautatis Incorporated 96
Viventia Biotechnologies Inc. 97
Merus B.V. 98
Pique Therapeutics 99
Inserm Transfert SA 100
Isofol Medical AB 101
Celtic Pharmaceutical Holdings L.P. 102
DEKK-TEC, Inc. 103
IkerChem S.L. 104
ISA Pharmaceuticals B.V. 105
TAU Therapeutics, LLC 106
GlycaNova Norway AS 107
Colon Cancer – Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Route of Administration 110
Assessment by Molecule Type 112
Drug Profiles 115
IMO-2055 - Drug Profile 115
cixutumumab - Drug Profile 117
vandetanib - Drug Profile 120
GSK-923295 - Drug Profile 126
LOR-1284 - Drug Profile 128
IL-17E - Drug Profile 129
LOR-253 - Drug Profile 130
CU-903 - Drug Profile 132
Im-01 - Drug Profile 133
MDRG-01 - Drug Profile 134
mi-APO - Drug Profile 135
ICT-037 - Drug Profile 136
ATI-1150 - Drug Profile 137
Chk-1 Inhibitor Programme - Drug Profile 138
FLT-3 Program - Drug Profile 140
FP-1039 - Drug Profile 141
Drug Targeting Carbonic Anhydrase IX - Drug Profile 143
Drug Targeting Carcinoembryonic Antigen - Drug Profile 144
COTI-2 - Drug Profile 145
XMT-1001 - Drug Profile 148
CGEN-25008 - Drug Profile 150
TLK-58747 - Drug Profile 151
OVI-117 - Drug Profile 152
AB-16B5 - Drug Profile 153
PMX-2058 - Drug Profile 154
AL-3818 - Drug Profile 155
VLN-244 - Drug Profile 156
OncoVAX - Drug Profile 157
Kevetrin - Drug Profile 159
BP-100-1.02 - Drug Profile 162
CVA-21 - Drug Profile 163
BNC-105 - Drug Profile 167
ATN-658 - Drug Profile 169
corticorelin acetate - Drug Profile 170
lurbinectedin - Drug Profile 172
demcizumab - Drug Profile 174
PAT-CM1 - Drug Profile 177
RX-0183 - Drug Profile 178
X-379 - Drug Profile 179
AF-122 - Drug Profile 180
CG-201 - Drug Profile 181
PHA-793887 - Drug Profile 183
rebastinib - Drug Profile 184
Personalized Peptide Vaccine - Drug Profile 186
OXY-111A - Drug Profile 187
TTT-3002 - Drug Profile 188
taurolidine - Drug Profile 189
BNC-105-P - Drug Profile 190
Peptide Cancer Vaccine + [basiliximab] - Drug Profile 192
ETBX-011 - Drug Profile 193
AEZS-131 - Drug Profile 195
Colon Cancer Vaccine - Drug Profile 196
Drugs For Cancer - Drug Profile 197
X-480 - Drug Profile 198
PT-128 - Drug Profile 199
Probodies Program - Drug Profile 200
VBx-011 - Drug Profile 201
PMX-500 - Drug Profile 202
eflornithine hydrochloride + sulindac - Drug Profile 203
PAT-SM3 - Drug Profile 205
PAT-SM5 - Drug Profile 206
CIGB-247 - Drug Profile 207
bevacizumab biosimilar - Drug Profile 208
DPK-M2 - Drug Profile 209
EC-7072 - Drug Profile 210
DPK-M1 - Drug Profile 211
TTL-1177 - Drug Profile 212
GO-203-2c - Drug Profile 213
Aurora Kinases + FLT-3 Kinase Program - Drug Profile 214
OXT-922 - Drug Profile 216
rhErbB3-f - Drug Profile 217
BACPT DP - Drug Profile 219
Project PFKFB-3 - Drug Profile 220
PMX-290 - Drug Profile 222
Tetrandrine - Drug Profile 223
²¹²Pb-TCMC-Trastuzumab - Drug Profile 225
5B1 - Drug Profile 227
ORB-0001 - Drug Profile 228
TVI-Colon-1 - Drug Profile 229
Corvlysis - Drug Profile 230
CFAK-Y15 - Drug Profile 231
MG-1102 - Drug Profile 232
naproxen - Drug Profile 233
NO-naproxen - Drug Profile 234
TBL-0306C - Drug Profile 235
BNC-101 - Drug Profile 236
Mobilan - Drug Profile 237
AL-2846 - Drug Profile 238
CG-0070-IT - Drug Profile 239
BKT-150 IV - Drug Profile 240
EC-8042 - Drug Profile 241
NOV-110401 - Drug Profile 243
PAT-SM4 - Drug Profile 244
JRP-890 - Drug Profile 245
JRP-980 - Drug Profile 246
QBECO SSI - Drug Profile 247
Drug Adaptation Program - Drug Profile 249
Tumor Metabolism Program - Drug Profile 250
Tumor Metabolism Program TBN - Drug Profile 251
Microtubule Binding Agents Programme - Drug Profile 252
Aplysiatoxin Derivative - Drug Profile 253
BBR-3610 - Drug Profile 254
MCT-1 Inhibitors - Drug Profile 255
Drugs Targeting Thymidylate Synthase And Dihydrofolate Reductase - Drug Profile 257
MUC1 Peptide Vaccine - Drug Profile 258
Imidazoles - Drug Profile 259
GDOX-Related Molecules - Drug Profile 260
OXT-328 - Drug Profile 261
Nampt Inhibitors - Drug Profile 263
largazole - Drug Profile 264
Drug For Solid Cancers - Drug Profile 266
DT-330 - Drug Profile 267
Selective HDAC-3 Inhibitors - Drug Profile 268
LFA-1 Antagonists - Drug Profile 269
ONC-201 - Drug Profile 270
ONC-301 - Drug Profile 271
ET-003 - Drug Profile 272
pTM-NRP1 - Drug Profile 273
ACVA DNA Vaccine - Drug Profile 274
E-804 - Drug Profile 275
JPH-203 - Drug Profile 276
Anti-EGFR-ATEP - Drug Profile 277
TAG-2 Humanized Antibody - Drug Profile 278
MM-10300 - Drug Profile 279
Aspirin Analogs - Drug Profile 280
Ultra IGFBP-2 - Drug Profile 281
Bisnaphthalimido Derivatives - Drug Profile 282
SNX-9 Class Compounds - Drug Profile 283
JP-11646 - Drug Profile 284
KT-220 - Drug Profile 285
PC-21 - Drug Profile 286
Copper Based Compounds - Drug Profile 287
Colon Cancer Therapeutics – Drug Profile Updates 288
Colon Cancer Therapeutics – Discontinued Products 321
Colon Cancer Therapeutics - Dormant Products 322
Colon Cancer – Product Development Milestones 329
Featured News & Press Releases 329

Appendix 337
Methodology 337
Coverage 337
Secondary Research 337
Primary Research 337
Expert Panel Validation 337
Contact Us 338
Disclaimer 338

Number of Products Under Development for Colon Cancer, H2 2013 22
Products under Development for Colon Cancer Comparative Analysis, H2 2013 23
Number of Products under Development by Companies, H2 2013 25
Number of Products under Development by Companies, H2 2013 (Contd..1) 26
Number of Products under Development by Companies, H2 2013 (Contd..2) 27
Number of Products under Development by Companies, H2 2013 (Contd..3) 28
Number of Products under Development by Companies, H2 2013 (Contd..4) 29
Number of Products under Development by Companies, H2 2013 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H2 2013 32
Comparative Analysis by Late Stage Development, H2 2013 33
Comparative Analysis by Mid Clinical Stage Development, H2 2013 34
Comparative Analysis by Early Clinical Stage Development, H2 2013 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 36
Products under Development by Companies, H2 2013 37
Products under Development by Companies, H2 2013 (Contd..1) 38
Products under Development by Companies, H2 2013 (Contd..2) 39
Products under Development by Companies, H2 2013 (Contd..3) 40
Products under Development by Companies, H2 2013 (Contd..4) 41
Products under Development by Companies, H2 2013 (Contd..5) 42
Products under Development by Companies, H2 2013 (Contd..6) 43
Products under Development by Companies, H2 2013 (Contd..7) 44
Products under Investigation by Universities/Institutes, H2 2013 45
AstraZeneca PLC, H2 2013 46
Eli Lilly and Company, H2 2013 47
Viralytics Ltd., H2 2013 48
Bioneer Corporation, H2 2013 49
Celltrion, Inc., H2 2013 50
Bio-Path Holdings, Inc., H2 2013 51
Geistlich Pharma AG, H2 2013 52
Aphios Corporation, H2 2013 53
Cell Therapeutics, Inc., H2 2013 54
Enzo Biochem, Inc., H2 2013 55
AEterna Zentaris Inc., H2 2013 56
ImmunoCellular Therapeutics, Ltd., H2 2013 57
Idera Pharmaceuticals, Inc., H2 2013 58
Lorus Therapeutics Inc, H2 2013 59
Bio-Bridge Science, Inc., H2 2013 60
Bionomics Limited, H2 2013 61
Cleveland BioLabs, Inc., H2 2013 63
OncoVista Innovative Therapies, Inc., H2 2013 64
Compugen Ltd., H2 2013 65
Patrys Limited, H2 2013 66
Critical Outcome Technologies Inc., H2 2013 67
Curis, Inc., H2 2013 68
Cytokinetics, Inc, H2 2013 69
Telik, Inc., H2 2013 70
Dendreon Corporation, H2 2013 71
Choongwae Pharma Corp, H2 2013 72
Green Cross Corporation, H2 2013 73
Sareum Holdings plc, H2 2013 74
Transgene Biotek Ltd, H2 2013 75
Rexahn Pharmaceuticals, Inc., H2 2013 76
MabVax Therapeutics, Inc., H2 2013 77
Nanobiotix, H2 2013 78
Cancer Research Technology Limited, H2 2013 79
Multimmune GmbH, H2 2013 80
Nerviano Medical Sciences S.r.l., H2 2013 81
Med Discovery SA, H2 2013 82
Provecs Medical GmbH, H2 2013 83
Alethia Biotherapeutics Inc., H2 2013 84
NormOxys, Inc., H2 2013 85
OncoMed Pharmaceuticals, Inc., H2 2013 86
Five Prime Therapeutics, Inc., H2 2013 87
Kalos Therapeutics, Inc., H2 2013 88
Azaya Therapeutics, Inc., H2 2013 90
Deciphera Pharmaceuticals, LLC, H2 2013 91
Mersana Therapeutics, Inc., H2 2013 92
Affichem, H2 2013 93
Advenchen Laboratories, LLC, H2 2013 94
Pharminox Limited, H2 2013 95
NovaLead Pharma Pvt. Ltd., H2 2013 96
Vaccinogen, Inc., H2 2013 97
Etubics Corporation, H2 2013 98
Cellceutix Corporation, H2 2013 100
PharmaMar, S.A., H2 2013 101
TVAX Biomedical, LLC, H2 2013 102
CG Therapeutics, Inc., H2 2013 103
Biokine Therapeutics Ltd., H2 2013 104
Tautatis Incorporated, H2 2013 105
Viventia Biotechnologies Inc., H2 2013 106
Merus B.V., H2 2013 107
Pique Therapeutics, H2 2013 108
Inserm Transfert SA, H2 2013 109
Celtic Pharmaceutical Holdings L.P., H2 2013 111
DEKK-TEC, Inc., H2 2013 112
IkerChem S.L., H2 2013 113
TAU Therapeutics, LLC, H2 2013 115
GlycaNova Norway AS, H2 2013 116
Assessment by Monotherapy Products, H2 2013 117
Assessment by Combination Products, H2 2013 118
Assessment by Stage and Route of Administration, H2 2013 120
Assessment by Stage and Molecule Type, H2 2013 123
Colon Cancer Therapeutics Drug Profile Updates 297
Colon Cancer Therapeutics Discontinued Products 330
Colon Cancer Therapeutics Dormant Products 331
Colon Cancer Therapeutics Dormant Products (Contd..1) 332
Colon Cancer Therapeutics Dormant Products (Contd..2) 333
Colon Cancer Therapeutics Dormant Products (Contd..3) 334
Colon Cancer Therapeutics Dormant Products (Contd..4) 335
Colon Cancer Therapeutics Dormant Products (Contd..5) 336
Colon Cancer Therapeutics Dormant Products (Contd..6) 337
Number of Products under Development for Colon Cancer, H2 2013 22
Products under Development for Colon Cancer Comparative Analysis, H2 2013 23
Products under Development by Companies, H2 2013 24
Products under Investigation by Universities/Institutes, H2 2013 31
Late Stage Products, H2 2013 33
Mid Clinical Stage Products, H2 2013 34
Early Clinical Stage Products, H2 2013 35
Discovery and Pre-Clinical Stage Products, H2 2013 36
Assessment by Monotherapy Products, H2 2013 117
Assessment by Combination Products, H2 2013 118
Assessment by Route of Administration, H2 2013 119
Assessment by Stage and Route of Administration, H2 2013 120
Assessment by Molecule Type, H2 2013 121
Assessment by Stage and Molecule Type, H2 2013 122